Zhang L, Chen W, Wang XM, Zhang SQ. Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report. World J Clin Cases 2022; 10(26): 9398-9403 [PMID: 36159401 DOI: 10.12998/wjcc.v10.i26.9398]
Corresponding Author of This Article
Lan Zhang, Doctor, PhD, Assistant Professor, Department of Hematology, The First Hospital of Shanxi Medical University, No. 89 Xinjian Road, Taiyuan 030001, Shanxi Province, China. qiqi994@sina.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2022; 10(26): 9398-9403 Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9398
Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
Lan Zhang, Wei Chen, Xiao-Min Wang, Shu-Qing Zhang
Lan Zhang, Wei Chen, Xiao-Min Wang, Shu-Qing Zhang, Department of Hematology, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Author contributions: Zhang L, Wang XM, Zhang SQ are responsible for the treatment of patient; Zhang L analyzed the data and wrote the manuscript; Chen W contributed coordination and manuscript review; all authors have read and approve the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lan Zhang, Doctor, PhD, Assistant Professor, Department of Hematology, The First Hospital of Shanxi Medical University, No. 89 Xinjian Road, Taiyuan 030001, Shanxi Province, China. qiqi994@sina.com
Received: April 14, 2022 Peer-review started: April 14, 2022 First decision: June 7, 2022 Revised: June 20, 2022 Accepted: August 6, 2022 Article in press: August 6, 2022 Published online: September 16, 2022 Processing time: 140 Days and 18.4 Hours
Core Tip
Core Tip: Cytokine release syndrome-induced rhabdomyolysis followed by chimeric antigen receptor-T (CAR-T) therapy treatment has not been previously reported. We report a case of a 22-year-old woman with relapsed acute lymphoblastic leukemia obtained sequential cluster of differentiation (CD) 19 and CD22 CAR-T cells infusion. This patient experienced grade 3 cytokine release syndrome with RM, mild hypotension requiring intravenous fluids, and mild hypoxia and was managed effectively with the interleukin-6 receptor antagonist tocilizumab. This patient had no signs of immune effector cell-associated neurologic syndrome. Restaging scans 30 d post CAR-T therapy demonstrated a complete remission, and the symptoms of muscle weakness improved through rehabilitation. Therefore, it is necessary to monitor myoglobin levels when a patient presents with symptoms of myalgia.
